Metabolic Enzyme/Protease MAPK/ERK Pathway Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage GPCR/G Protein Immunology/Inflammation Anti-infection Apoptosis Membrane Transporter/Ion Channel NF-κB
Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB
Cichoriin

Cat. No.: HY-N8599

Cichoriin

2 Cited Publications

고객리뷰

Based on 2 publication(s) in Google Scholar

Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.9%
CAS No.: 531-58-8
화학식: C₁₅H₁₆O₉
분자량:340.28

보관:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Cichoriin Chemical Structure

CAS No.: 531-58-8

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (2)
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target^[1]^[5]

PPAR-γ

DPP-4

GLUT4

NLRP3 inflammasome

P2Y14 Receptor

All Dipeptidyl Peptidase Isoforms :

All p38 MAPK Isoforms :

All PPAR Isoforms :

All P2Y Receptor Isoforms :

All NOD-like Receptor (NLR) Isoforms :

All GLUT Isoforms :

All NF-κB Isoforms :

In Vitro

Cichoriin exhibits favorable binding affinity to multiple diabetes and cardiovascular targets, including α-amylase, α-glucosidase, DPP-IV, PPARγ, AMPK, GLUT-4, ACE and NF-κB, with binding energies ranging from -6.8 to -9.8 kcal/mol^[1].
Cichoriin (25-50 μM; 24 h) dose-dependently reduces free fatty acid (FFA)-induced lipid accumulation in HepG2 cells, AML12 cells, and primary mouse hepatocytes^[3].
Cichoriin (25-50 μM; 24 h) reduces reactive oxygen species levels in FFA-induced AML12 mouse hepatocytes^[3].
Cichoriin (50 μM; 24 h) activates the AMPK pathway by increasing the phosphorylation levels of AMPKα and ACC, and upregulates the expression of CPT-1A in primary mouse hepatocytes treated with free fatty acids (FFA)^[3].
Cichoriin (50 μM; 24 h) inhibits the migration and activation of hepatic stellate cells (HSC) (reducing the expression of Col I and α-SMA) in an indirect co-culture system by regulating paracrine signals in primary mouse hepatocytes treated with FFA^[3].
Cichoriin (25-50 μM; 24 h) inhibits PDGF-AA secretion from lipotoxic primary mouse hepatocytes^[3].
The lipid-lowering, anti-inflammatory, and PDGF-AA inhibitory effects of Cichoriin on free fatty acid (FFA)-treated primary mouse hepatocytes, as well as the anti-fibrotic effect on co-cultivated hepatic stellate cells (HSCs), all depend on the activation of AMPK^[3].
Cichoriin (50-200 μM; 24 h) significantly inhibits monosodium urate crystal-induced release of IL-1β and IL-18, as well as protein expression of NLRP3, Caspase-1, GSDMD and ASC in differentiated THP-1 macrophages^[5].
Cichorin (50-200 μM; 24 h) effectively inhibits monosodium urate crystal-driven macrophage pyroptosis^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

Primary mouse hepatocytes (with FFA-induced lipotoxicity)
Concentration:

50 μM
Incubation Time:

24 h (concurrent with FFA treatment)
Result:

Significantly increased phosphorylation levels of AMPKα and ACC compared to FFA-only treated cells.
Upregulated CPT-1A protein expression compared to FFA-only treated cells.

Cell Migration Assay^[3]

Cell Line:

Indirect Transwell co-culture of primary mouse hepatocytes and primary mouse hepatic stellate cells (HSCs) (with FFA-induced hepatocyte lipotoxicity)
Concentration:

50 μM
Incubation Time:

24 h (incubation with hepatocytes, prior to co-culture)
Result:

Significantly inhibited HSC migration (reduced wound closure rate) compared to FFA-only treated hepatocytes.
Downregulated protein expression of collagen I (Col I) and alpha-smooth muscle actin (α-SMA) in co-cultured HSCs compared to FFA-only treated hepatocytes.

ELISA Assay^[3]

Cell Line:

Primary mouse hepatocytes (with FFA-induced lipotoxicity)
Concentration:

25 and 50 μM
Incubation Time:

24 h
Result:

Reduced FFA-induced PDGF-AA secretion from primary mouse hepatocytes compared to FFA-only treated hepatocytes.

ELISA Assay^[5]

Cell Line:

THP-1 macrophages
Concentration:

25, 100 and 200 μM
Incubation Time:

Pre-treatment for 1 hour, followed by stimulation with sodium urate crystals for 23 hours
Result:

Significantly inhibited the release of IL-1β and IL-18.

Western Blot Analysis^[5]

Cell Line:

THP-1 macrophages
Concentration:

25, 100 and 200 μM
Incubation Time:

Pre-treatment for 1 hour, followed by stimulation with sodium urate crystals for 23 hours
Result:

Significantly inhibited the protein expression levels of NLRP3, Caspase-1, GSDMD and ASC.

In Vivo

Cichoriin (50-100 mg/kg; p.o.; daily; 4 weeks) mitigates high-fat diet-induced obesity and associated metabolic, oxidative, and histopathological dysfunctions in rats in a dose-dependent manner^[2].
Cichoriin (100-200 mg/kg/day; oral gavage; daily; 6 weeks) dose-dependently alleviates GAN diet-induced MASH and associated liver fibrosis in male C57BL/6J mice via AMPK pathway activation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (male, 100-150 g initial weight, high-fat diet-induced obesity)^[2]
Dosage:

50 mg/kg; 100 mg/kg
Administration:

p.o.; daily; 4 weeks
Result:

Reduced body-weight gain to 142 g, BMI to 0.58 g/cm², liver weight to 7.0 g, visceral fat weight to 4.7 g.
Improved serum lipid profile to total cholesterol 125 mg/dL, triglycerides 48 mg/dL, low-density lipoprotein cholesterol 93 mg/dL, high-density lipoprotein cholesterol 23 mg/dL, LDL-C/HDL-C ratio 4.2.
Lowered hepatic malondialdehyde to 107.2 nmol/g tissue, renal malondialdehyde to 78.4 nmol/g tissue, and increased hepatic reduced glutathione to 271 mg/g tissue, renal reduced glutathione to 286 mg/g tissue.
Upregulated peroxisome proliferator-activated receptor gamma mRNA and protein expression in adipose tissue.
Showed moderate improvement in heart, kidney, and liver tissue architecture with reduced tissue damage compared to HFD controls.
Reduced body-weight gain to 123 g, BMI to 0.55 g/cm², liver weight to 6.7 g, kidney weight to 1.2 g, heart weight to 0.9 g, visceral fat weight to 3.1 g.
Improved serum lipid profile to total cholesterol 85 mg/dL, triglycerides 40 mg/dL, low-density lipoprotein cholesterol 44 mg/dL, high-density lipoprotein cholesterol 33 mg/dL, LDL-C/HDL-C ratio 1.4.
Normalized serum alanine transaminase, aspartate transaminase, urea, creatinine, and creatine kinase MB levels to near-control values.
Lowered hepatic malondialdehyde to 96.9 nmol/g tissue, renal malondialdehyde to 64.3 nmol/g tissue, and increased hepatic reduced glutathione to 325 mg/g tissue, renal reduced glutathione to 339 mg/g tissue.
Upregulated peroxisome proliferator-activated receptor gamma mRNA and protein expression in adipose tissue to levels comparable to the atorvastatin control.
Showed marked improvement in heart, kidney, and liver tissue architecture with minimal residual damage compared to HFD controls.

Animal Model:

C57BL/6J (male, 8-10 weeks old, 20-25 g, GAN diet-induced MASH)^[3]
Dosage:

100 mg/kg/day; 200 mg/kg/day
Administration:

oral gavage; daily; 6 weeks
Result:

Significantly reduced body weight, liver index, and blood glucose levels in a dose-dependent manner.
Decreased serum levels of AST, ALT, LDH, AKP, TC, TG, LDL-C, and NEFA, while increased HDL-C levels.
Attenuated hepatic steatosis, inflammation scores, and NAFLD Activity Score (NAS), with reduced liver lipid content (Oil Red O staining area, hepatic TC, TG).
Lowered hepatic AST, ALT, and LDH levels.
Reduced liver fibrosis, as shown by decreased Masson’s trichrome staining area, hepatic hydroxyproline levels, liver Ishak score, and serum fibrosis biomarkers (HA, LN, Col IV, Pro III).
Dose-dependently suppressed mRNA expression of fibrosis-related genes (Col3a1, Col1a1, Acta2, Tgfb1), reduced Smad2 and Smad4 staining intensity, and downregulated protein expression of α-SMA, TGF-β1, Col III, and Col I.
Decreased hepatic F4/80-positive macrophage density, upregulated hepatic SOD, GSH, and CAT levels, and reduced hepatic MDA content.
Lowered hepatic levels of TNF-α, IL-6, and IL-1β, with downregulated protein levels of p-IKKβ and p-NF-κB p65, and upregulated IκBα.
Enhanced phosphorylation of AMPK (Thr172) and ACC (Ser79) at 200 mg/kg dose, increasing p-AMPK/total AMPK and p-ACC/total ACC ratios.
Reversed GAN diet-induced upregulation of pro-inflammatory factors, fibrogenic markers, and lipogenic enzymes, while restored expression of fatty acid β-oxidation and insulin signaling proteins at 200 mg/kg dose.

Chemical Information

CAS No. 531-58-8
Appearance Solid
분자량 340.28
화학식 C₁₅H₁₆O₉
Color White to off-white
SMILES

OC1=C(C=C2C(C=CC(O2)=O)=C1)O[C@@H]3O[C@@H]([C@H]([C@@H]([C@H]3O)O)O)CO
Structure Classification
- Phenylpropanoids
- Coumarins
- Phenols
- Monophenols
Initial Source
- Plants
- other families
선적

Room temperature in continental US; may vary elsewhere.
보관

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (2)

All

Sort by:

Journal Impact Factor

Bioorg Chem

Discovery of cyanidin-3-O-galactoside as a novel CNT2 inhibitor for the treatment of hyperuricemia. [Abstract]

2025 Jan:154:108108. PMID: 39753042
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607

용액&용해도

In Vitro:

DMSO : 100 mg/mL (293.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9388 mL

14.6938 mL

29.3876 mL

5 mM

0.5878 mL

2.9388 mL

5.8775 mL

10 mM

0.2939 mL

1.4694 mL

2.9388 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (292 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sishu NK, et al. Cichoriin, a coumarin glycoside with antidiabetic effect and cardioprotective activity against H₂O₂ induced oxidative stress in H9c2 cells: in-vitro and in-silico study. Free Radic Biol Med. 2025;241:671-688. [Content Brief]

[2]. Khalil HE, et al. Cichoriin, a Biocoumarin, Mitigates Oxidative Stress and Associated Adverse Dysfunctions on High-Fat Diet-Induced Obesity in Rats. Life (Basel). 2022;12(11):1731. Published 2022 Oct 28. [Content Brief]

[3]. Zhao Y, et al. Cichoriin suppresses hepatic lipid accumulation and fibrosis in mice metabolic dysfunction associated steatohepatitis via the AMPK pathway. Biochem Pharmacol. 2026;245:117630. [Content Brief]

[4]. Rivero-Segura NA, et al. In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19. Biomolecules. 2021;11(2):216. Published 2021 Feb 4. [Content Brief]

[5]. Wu X, et al. Mechanistic insights into how cichoriin inhibits P2Y14R to suppress MSU-induced gouty inflammation. BMC Biotechnol. 2026 Apr 15.
[Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9388 mL	14.6938 mL	29.3876 mL	73.4689 mL
	5 mM	0.5878 mL	2.9388 mL	5.8775 mL	14.6938 mL
	10 mM	0.2939 mL	1.4694 mL	2.9388 mL	7.3469 mL
	15 mM	0.1959 mL	0.9796 mL	1.9592 mL	4.8979 mL
	20 mM	0.1469 mL	0.7347 mL	1.4694 mL	3.6734 mL
	25 mM	0.1176 mL	0.5878 mL	1.1755 mL	2.9388 mL
	30 mM	0.0980 mL	0.4898 mL	0.9796 mL	2.4490 mL
	40 mM	0.0735 mL	0.3673 mL	0.7347 mL	1.8367 mL
	50 mM	0.0588 mL	0.2939 mL	0.5878 mL	1.4694 mL
	60 mM	0.0490 mL	0.2449 mL	0.4898 mL	1.2245 mL
	80 mM	0.0367 mL	0.1837 mL	0.3673 mL	0.9184 mL
	100 mM	0.0294 mL	0.1469 mL	0.2939 mL	0.7347 mL

Cichoriin

2 Cited Publications

100 mg 견적 받기

Subscribe to the

MedChemExpress

Newsletter

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Cichoriin

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Amino Acid Metabolism Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cichoriin

All Dipeptidyl Peptidase Isoforms

All p38 MAPK Isoforms

All PPAR Isoforms

All P2Y Receptor Isoforms

All NOD-like Receptor (NLR) Isoforms